Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This is a non-randomised clinical trial, in which participants will be assigned to one of two treatment arms. All participants will receive an oral dose of ipatasertib once daily on days 1-21 of each 28 day cycle, and atezolizumab intravenously on days 1 and 15 of each 28 day cycle. Depending on their assignment, participants will also receive either paclitaxel or nab-paclitaxel by intravenous infusion on Days 1, 8 and 15 of each 28 day cycle.